1887
Volume 2000, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Erectile dysfunction (ED) is a common problem in males. About half of all men over 40 years of age suffer from some degree of ED and in half of them the dysfunction is moderate or complete. More than 90% of men with ED do not seek treatment either because they are not comfortable with the subject or because, until very recently, the effective treatments available were invasive. Recent publicity about male sexual health and the availability, for the first time, of an oral medication which is specific and effective in the management of ED have made male patients more vocal about their sexual problems, especially to their doctors. These developments have also made doctors more aware of the magnitude of this problem.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2000.2.8
2000-12-01
2019-08-20
Loading full text...

Full text loading...

References

  1. 1. Feldman   HA., Goldstein   I., Hatzichriston   DG., Krane   RJ., Mckinlay   JB. . Impotence and its medical and psychological correlates: results of the Massachusettes Male Aging Study. . J Urol.   1994; ;   151 : 54– 61 .
    [Google Scholar]
  2. 2. Treating erectile dysfunction: a physician's guide. Pfizer pharmaceuticals monogram, Pfizer Inc., New York; 1998.
  3. 3. Laumann   EO., Paik   A., Rosen   RC. . Sexual dysfunction in the United States; prevalence and predictors. . JAMA . 1999; ;281: : 537– 544 .
    [Google Scholar]
  4. 4.   NIH Consensus Development Panel on Impotence. . JAMA . 1993; ;270: : 83– 90 .
    [Google Scholar]
  5. 5. Krauss   D. . The physiologic basis of male sexual dysfunction. . Hosp. Pract . 1983; ;2: : 193– 222 .
    [Google Scholar]
  6. 6. Lerner   SE., Melman   A., Christ   GJ. . A review of erectile dysfunction: new insignht and more questions. . J Urol.   1993; ;149: : 1246– 1255 .
    [Google Scholar]
  7. 7. Lo Piccolo   J., Daiss   S. . Contemporary Management of Impotence and Infertility. . In: Tanagho   EA., Lue   TF., McClure   RD. , eds. Baltimore: : Williams & Wilkins;   1988; ; : 104– 107 .
  8. 8. Masters   W., Johnson   V. . Human sexual inadequacy . Boston: : Little, Brown & Co.;   1970; .
    [Google Scholar]
  9. 9. Spark   R., White   R., Connoly   P. . Impotence is not always psychogenic. New insights into hypothalamic-pituitary-gonadal dysfunction. . JAMA . 1980; ;243: : 750– 755 .
    [Google Scholar]
  10. 10. Bancroft   J. . Testosterone therapy for low sexual interest and erectile dysfunction in man: a controlled study. . Br J Psychiatry . 1984; ;14: : 146– 151 .
    [Google Scholar]
  11. 11. Seagraves   R., Schoenberg   H., Zarins   C., Knopf   J., Carnic   P. . Discrimination of organic versus psychological impotence with the DSFI: a failure to replicate. . J Sex Marital Ther.   1981; ;7: : 230– 238 .
    [Google Scholar]
  12. 12. Carrier   S., Brock   G., Kour   NW., Lue   TF. . Pathophysiology of erectile dysfunction. . Urology.   1993; ;42: : 468– 481 .
    [Google Scholar]
  13. 13. Benet   AE., Melman   A. . The epidemiology of erectile dysfunction. . Urol Clin North Am . 1995; ;22: : 699– 709 .
    [Google Scholar]
  14. 14. Weirman   ME., Casel   CK. . Erectile dysfunction: a multifaceted disorder. . Hosp Pract. Oct.   1998; ;18: : 65– 90 .
    [Google Scholar]
  15. 15. Bartlik   B., Cocsis   JH., Legere   R. et al. Sexual dysfunctions secondary to depressive disorders. . J Sex Marital Ther.   1999; ;2: 2 : 52– 60 .
    [Google Scholar]
  16. 16. Shah sigh   R. . Is a drug effect part of your patient's complaint of impotence ?.   Contemp Urol . 1993; ;5: : 51– 58 .
    [Google Scholar]
  17. 17. Finger   WW., Lung   M., Stagle   MA. . Medications that may contribute to sexual disorders. . J Fam Pract.   1997; ;44: : 33– 43 .
    [Google Scholar]
  18. 18. Merrill   JM., Laux   LF., Thornby   JI. . Why doctors have difficulty with sex histories. . South Med J; . 1990; ;83: : 613– 617 .
    [Google Scholar]
  19. 19. Tudiver   F., Talbot   Y. . Why don't men seek help ? Family physicians perspectives on help-seeking behavior in men. . J Fam Pract.   1999; ;48: : 47– 52 .
    [Google Scholar]
  20. 20. Rosen   RC., Riley   A., Wagner   G., Osterloh   IH., Kirkpatrick   J., Mishra   A. . The International Index of Erectile Function (IIEF): a multidimentional scale for assessment of erectile dysfunction. . Urology . 1997; ;49: : 822– 830 .
    [Google Scholar]
  21. 21. Lue   TF. . Impotence: a patient's goal-directed approach to treatment. . World J Urol . 1990; ;8: : 67– 74 .
    [Google Scholar]
  22. 22. Althof   SE., Sefte   AD. . The evaluation and management of erectile dysfunction. . Psychiatr Clin North Am . 1995; ;18: : 171– 191 .
    [Google Scholar]
  23. 23. Gunnarsson   OT., Judge   JO. . Exercise at midlife: how and why to prescribe it for sedentary patients. . Geriatrics.   1997; ;52: : 71– 80 .
    [Google Scholar]
  24. 24. Muller   JE., Mittleman   MA., Maclure   M. et al. Triggering myocardial infarction by sexual activity. . JAMA . 1996; ;275: : 1405– 1409 .
    [Google Scholar]
  25. 25. Goldstein   I., Kue   TF., Padma-Nathan   H., Rosen   RC., Steers   WC., Wickers   PA. . for the sildenafil study group. Oral sildenafil in the treatment of erectile dysfunction. . N Engl J Med.   1998; ;338: : 1397– 1404 .
    [Google Scholar]
  26. 26. Cheitlin   MD., Hutter   AM., Brindis   RG. et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA Expert Consensus Document. . J Am Coll Cardiol.   1999; ;33: : 273– 282 .
    [Google Scholar]
  27. 27. Nicker son   M., Collier   B. . Drugs inhibiting adrenergic nerves and structures innervated by them. . In: Goodman   L., Gilman   A. , eds. The pharmacological basis of therapeutics . New York: : McMillan;   1975; ; : 533– 564 .
    [Google Scholar]
  28. 28. Kunelius   P., Hakkinen   J., Lukkarinen   O. . Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence ?.   Urology . 1997; ;49: : 441– 444 .
    [Google Scholar]
  29. 29. Porst   H. . The rationale for prostaglandin E] in erectile failure: a survey of worldwide experience. . J Urol . 1996; ;155: : 802– 815 .
    [Google Scholar]
  30. 30. Padma-Nathan   H., Hellstrom   WJ., Kaiser   FE. et al. Treatment of men with erectile dysfunction with transurethral alprostadil. . N Engl J Med . 1997; ;336: : 1– 7 .
    [Google Scholar]
  31. 31. Brindly   GS. . Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. . Br J Psychiatry . 1983; ;143: : 332– 339 .
    [Google Scholar]
  32. 32. Linet   01., Prince   FG., for the alprostadil study group. . Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. . N Engl J Med . 1996; ;334: : 873– 877 .
    [Google Scholar]
  33. 33. Mulhall   JP., Jahoda   AE., Cairney   M. et al. The causes of patient dropout from penile self injection therapy for impotence. . J Urol . 1999; ;162: 4 : 1291– 1294 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2000.2.8
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error